United Therapeutics Corporation Reports First Quarter 2022 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
United Therapeutics Corp. (UTHR) PT Raised to $250 at Cowen
May 4, 2022 3:47 PM EDTCowen analyst Joseph Thome raised the price target on United Therapeutics Corp. (NASDAQ: UTHR) to $250.00 (from $240.00) while maintaining an Outperform rating following earnings.
The analyst commented, "UTHR reported strong revenues across the franchise to beat consensus expectations for the quarter. A positive... More
United Therapeutics (UTHR) Tops Q1 EPS by $1.69
May 4, 2022 6:10 AM EDTUnited Therapeutics (NASDAQ: UTHR) reported Q1 EPS of $5.03, $1.69 better than the analyst estimate of $3.34. Revenue for the quarter came in at $461.9 million versus the consensus estimate of $420.02 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
... More